Aug 12, 2020
NS Pharma's VILTEPSO(TM) (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy
Aug 11, 2020
FSHD Society is funding the expansion of the FSHD Clinical Trial Research Network
Jun 09, 2020
CureDuchenne Ventures Announces The "CureDuchenne Ventures 2020 Pitch Contest," To Award Two $25,000 Prizes For Novel Ideas In Duchenne Muscular Dystrophy Therapy Development
May 27, 2020
Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Children's Health and UT Southwestern Medical Center
May 26, 2020
Eiger to Present at Jefferies Virtual Healthcare Conference 2020
May 26, 2020
NS Pharma Announces Publication of Clinical Trial Data for Viltolarsen in DMD Patients in JAMA Neurology
May 07, 2020
Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030: DelveInsight
Apr 30, 2020
NS-065/NCNP-01 (Viltolarsen) Drug & Industry Report 2020-2030
Apr 30, 2020
Global Casimersen Drug Insights, 2020-2030
Apr 30, 2020
Edasalonexent Drug Insights Report 2020-2030: Mechanism of Action, Dosage & Administration, Route of Synthesis, Research & Development Activity
Apr 02, 2020
AMRA Medical and Fulcrum Therapeutics Develop MRI Method for Multi-site Neuromuscular Clinical Trials
Apr 01, 2020
Parent Project Muscular Dystrophy Announces First Dual Pediatric & Adult Certified Duchenne Care Center, Kennedy Krieger Institute
Mar 31, 2020
Muscular Dystrophy Association to Host MDA Frontline COVID-19 Response with Dr. Barry Byrne, a Facebook Live Q&A on Protecting Neuromuscular Disease Community in Midst of COVID-19 Pandemic
Feb 12, 2020
Okayama University Research: The Molecular Pathogenesis of Muscular Dystrophy-associated Cardiomyopathy
Feb 03, 2020
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
Jan 08, 2020
Parent Project Muscular Dystrophy's Endurance Program -- Race to End Duchenne -- Celebrates 15 Years of Going the Distance to End Duchenne
Jan 07, 2020
Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
Dec 18, 2019
Parent Project Muscular Dystrophy Awards $465,000 Grant to The Ohio State University to Rescue Cardiac Dystrophin & Function in Duchenne Muscular Dystrophy
Dec 13, 2019
MDA Celebrates FDA Approval of Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping
Dec 12, 2019
FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation